ArticleiScience2021
Polyclonal F(ab')
Open access · goldAbstract read
In one paragraph
Article in iScience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.8field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19.Frontiers in immunology · 2024Trial
- Alpha Linolenic and Stearic Acids Modulate Genes Related to Viral Entry and Inflammatory Response in THP-1 Derived Macrophages Exposed to SARS-CoV-2.Food science & nutrition · 2025Article
- Long-Term Maintenance of High Neutralizing Anti-SARS-CoV-2 Antibodies Titres in Mares' Milk and Offspring Serum After Pregnant Mares Immunization With SARS-CoV-2 Spike Protein.Veterinary medicine and science · 2025Article
- Immunogenic Potential of Selected Peptides from SARS-CoV-2 Proteins and Their Ability to Block S1/ACE-2 Binding.Viruses · 2025Article
- Plaque Reduction Neutralization Test (PRNT) Accuracy in Evaluating Humoral Immune Response to SARS-CoV-2.Diseases (Basel, Switzerland) · 2024Article
- Neutralization of Different Variants of SARS-CoV-2 by a F(ab')2 Preparation from Sera of Horses Immunized with the Viral Receptor Binding Domain.Antibodies (Basel, Switzerland) · 2023Article
- Refinement of an ovine-based immunoglobulin therapy against SARS-CoV-2, with comparison of whole IgG versus F(ab')Scientific reports · 2023Article
- Heterologous Booster with BNT162b2 Induced High Specific Antibody Levels in CoronaVac Vaccinees.Vaccines · 2023Article
- PEGylation Prolongs the Half-Life of Equine Anti-SARS-CoV-2 Specific F(ab')International journal of molecular sciences · 2023Article
- SARS-CoV-2 Spike protein alters microglial purinergic signaling.Frontiers in immunology · 2023Article
- Therapeutic equine hyperimmune antibodies with high and broad-spectrum neutralizing activity protect rodents against SARS-CoV-2 infection.Frontiers in immunology · 2023Article
- Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.Frontiers in immunology · 2023Article
- SARS-CoV-2 spike protein inhibits megalin-mediated albumin endocytosis in proximal tubule epithelial cells.Biochimica et biophysica acta. Molecular basis of disease · 2022Article
- Influence of particle size on the SARS-CoV-2 spike protein detection using IgG-capped gold nanoparticles and dynamic light scattering.Materials today. Chemistry · 2022Article
- Equine immunoglobulin fragment F(ab')Clinical immunology (Orlando, Fla.) · 2022Article
- Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants.International journal of environmental research and public health · 2022Review
- Passive immunization with equine RBD-specific Fab protects K18-hACE2-mice against Alpha or Beta variants of SARS-CoV-2.Frontiers in immunology · 2022Article
- Equine Anti-SARS-CoV-2 Serum (ECIG) Binds to Mutated RBDs and N Proteins of Variants of Concern and Inhibits the Binding of RBDs to ACE-2 Receptor.Frontiers in immunology · 2022Article
- Immunogenicity of SARS-CoV-2 Trimeric Spike Protein Associated to Poly(I:C) Plus Alum.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 3 institutions in 1 country.
Luis Eduardo R CunhaVital Brazil Institute, Niterói, RJ 24230-410, Brazil.
Adilson A StoletVital Brazil Institute, Niterói, RJ 24230-410, Brazil.
Marcelo A StrauchVital Brazil Institute, Niterói, RJ 24230-410, Brazil.
Victor A R PereiraInstitute of Medical Biochemistry Leopoldo de Meis, National Center of Nuclear Magnetic Resonance Jiri Jonas, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil.
Carlos H DumardInstitute of Medical Biochemistry Leopoldo de Meis, National Center of Nuclear Magnetic Resonance Jiri Jonas, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil.
Andre M O GomesInstitute of Medical Biochemistry Leopoldo de Meis, National Center of Nuclear Magnetic Resonance Jiri Jonas, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil.
Fábio L MonteiroInstitute of Biology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil.
Luiza M HigaInstitute of Biology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil.
Patrícia N C SouzaVital Brazil Institute, Niterói, RJ 24230-410, Brazil.
Juliana G FonsecaVital Brazil Institute, Niterói, RJ 24230-410, Brazil.
Francisco E PontesVital Brazil Institute, Niterói, RJ 24230-410, Brazil.
Leonardo G R MeirellesVital Brazil Institute, Niterói, RJ 24230-410, Brazil.
José W M AlbuquerqueVital Brazil Institute, Niterói, RJ 24230-410, Brazil.
Carolina Q SacramentoImmunopharmacology Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil.
Natalia Fintelman-RodriguesImmunopharmacology Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil.
Tulio M LimaCell Culture Engineering Laboratory, COPPE, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-598, Brazil.
Renata G F AlvimCell Culture Engineering Laboratory, COPPE, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-598, Brazil.
Federico F MarsiliCell Culture Engineering Laboratory, COPPE, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-598, Brazil.
Marcella Moreira CaldeiraInstitute of Medical Biochemistry Leopoldo de Meis, National Center of Nuclear Magnetic Resonance Jiri Jonas, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil.
Russolina B ZingaliInstitute of Medical Biochemistry Leopoldo de Meis, National Center of Nuclear Magnetic Resonance Jiri Jonas, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil.
Guilherme A P de OliveiraInstitute of Medical Biochemistry Leopoldo de Meis, National Center of Nuclear Magnetic Resonance Jiri Jonas, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil.
Thiago M L SouzaImmunopharmacology Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil.
Alexandre S SilvaLaboratory of Technological Development in Virology (LADTV), Oswaldo Cruz Institute, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil.
Rodrigo MullerAnimal Experimentation Laboratory (LAEAN), Institute of Technology in Immunobiologicals, Bio-Manguinhos, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil.
Daniela Del Rosário Flores RodriguesLaboratory of Technological Development in Virology (LADTV), Oswaldo Cruz Institute, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil.
Luciana Jesus da CostaDepartment of Virology, Laboratory of Genetics and Immunology of Viral Infections, Institute of Microbiology Paulo de Goes, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ CEP 21941902 , Brazil.
Arthur Daniel R AlvesLaboratory of Technological Development in Virology (LADTV), Oswaldo Cruz Institute, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil.
Marcelo Alves PintoLaboratory of Technological Development in Virology (LADTV), Oswaldo Cruz Institute, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil.
Andréa C OliveiraInstitute of Medical Biochemistry Leopoldo de Meis, National Center of Nuclear Magnetic Resonance Jiri Jonas, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil.
Herbert L M GuedesImmunopharmacology Laboratory, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-902, Brazil.
Amilcar TanuriNational Institute of Science and Technology for Structural Biology and Bioimaging, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil.
Leda R CastilhoCell Culture Engineering Laboratory, COPPE, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-598, Brazil.
Jerson L SilvaInstitute of Medical Biochemistry Leopoldo de Meis, National Center of Nuclear Magnetic Resonance Jiri Jonas, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ 21941-901, Brazil.
Universidade Federal do Rio de Janeiro · BRFundação Oswaldo Cruz · BRInstituto Vital Brazil (Brazil) · BR
Funding
No grant is acknowledged in the PubMed record.
Abstract
We used the recombinant trimeric spike (S) glycoprotein in the prefusion conformation to immunize horses for the production of hyperimmune globulins against SARS-CoV-2. Serum antibody titers measured by ELISA were above 1:10
Indexed as
Biological sciencesEquine immunologyImmunology
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.